Dr. Jan Bruder, Max-Planck Institute for Molecular Biomedicine, discusses his work combining stem cells with automation to drive towards drug development for neurodegenerative diseases such as Parkinson’s and Motor Neuron Disease. In this presentation Dr. Bruder looks at the system requirements for drug screening and how they are crucial for better understanding of these increasingly common diseases.